Aseptic Meningitis after Amenamevir Treatment for Herpes Zoster in the First Branch of the Trigeminal Nerve

Amenamevir has been approved for the treatment of herpes zoster (HZ); however, its therapeutic efficacy against central nervous system (CNS) infection may be insufficient due to its low spinal fluid permeability. We herein report a case of aseptic meningitis in a 91-year-old Japanese man treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Itoh, Kazuhiro, Mitsuke, Yasuhiko, Wakahara, Mami, Yoshioka, Tatsuya, Otsuki, Nozomi, Suzuki, Yusuke, Kiriba, Chiyo, Kuwata, Atsushi, Sakamaki, Ippei, Iwasaki, Hiromichi, Tsutani, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556230/
https://www.ncbi.nlm.nih.gov/pubmed/35228415
http://dx.doi.org/10.2169/internalmedicine.8581-21
Descripción
Sumario:Amenamevir has been approved for the treatment of herpes zoster (HZ); however, its therapeutic efficacy against central nervous system (CNS) infection may be insufficient due to its low spinal fluid permeability. We herein report a case of aseptic meningitis in a 91-year-old Japanese man treated with amenamevir for HZ in the trigeminal nerve region. Several cases of CNS infection have been reported in patients receiving amenamevir treatment for HZ. Patients with CNS complications often have skin rashes near the trigeminal region. Thus, we should be alert for signs of CNS infection when administering amenamevir to patients with such rashes.

Ejemplares similares